Literature DB >> 20361239

Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Rayomand J Unwalla1, Jason B Cross, Sumeet Salaniwal, Adam D Shilling, Louis Leung, John Kao, Christine Humblet.   

Abstract

CYP2D6 is an important enzyme that is involved in first pass metabolism and is responsible for metabolizing ~25% of currently marketed drugs. A homology model of CYP2D6 was built using X-ray structures of ligand-bound CYP2C5 complexes as templates. This homology model was used in docking studies to rationalize and predict the site of metabolism of known CYP2D6 substrates. While the homology model was generally found to be in good agreement with the recently solved apo (ligand-free) X-ray structure of CYP2D6, significant differences between the structures were observed in the B' and F-G helical region. These structural differences are similar to those observed between ligand-free and ligand-bound structures of other CYPs and suggest that these conformational changes result from induced-fit adaptations upon ligand binding. By docking to the homology model using Glide, it was possible to identify the correct site of metabolism for a set of 16 CYP2D6 substrates 85% of the time when the 5 top scoring poses were examined. On the other hand, docking to the apo CYP2D6 X-ray structure led to a loss in accuracy in predicting the sites of metabolism for many of the CYP2D6 substrates considered in this study. These results demonstrate the importance of describing substrate-induced conformational changes that occur upon binding. The best results were obtained using Glide SP with van der Waals scaling set to 0.8 for both the receptor and ligand atoms. A discussion of putative binding modes that explain the distribution of metabolic sites for substrates, as well as a relationship between the number of metabolic sites and substrate size, are also presented. In addition, analysis of these binding modes enabled us to rationalize the typical hydroxylation and O-demethylation reactions catalyzed by CYP2D6 as well as the less common N-dealkylation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20361239     DOI: 10.1007/s10822-010-9336-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  71 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Metabolism of carteolol by cDNA-expressed human cytochrome P450.

Authors:  S Kudo; M Uchida; M Odomi
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 5.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

6.  Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6.

Authors:  S W Ellis; G P Hayhurst; G Smith; T Lightfoot; M M Wong; A P Simula; M J Ackland; M J Sternberg; M S Lennard; G T Tucker
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

7.  Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.

Authors:  Chris de Graaf; Chris Oostenbrink; Peter H J Keizers; Tushar van der Wijst; Aldo Jongejan; Nico P E Vermeulen
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

8.  Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking.

Authors:  Jozef Hritz; Anita de Ruiter; Chris Oostenbrink
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

9.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.

Authors:  S W Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; M S Lennard; C R Wolf; G T Tucker
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

10.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.

Authors:  N L Kerry; A A Somogyi; F Bochner; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

View more
  11 in total

Review 1.  Protein modeling: what happened to the "protein structure gap"?

Authors:  Torsten Schwede
Journal:  Structure       Date:  2013-09-03       Impact factor: 5.006

2.  IDSite: An accurate approach to predict P450-mediated drug metabolism.

Authors:  Jianing Li; Severin T Schneebeli; Joseph Bylund; Ramy Farid; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2011-11-08       Impact factor: 6.006

3.  Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.

Authors:  Takeshi Akiyoshi; Takashi Saito; Saori Murase; Mitsue Miyazaki; Norie Murayama; Hiroshi Yamazaki; F Peter Guengerich; Katsunori Nakamura; Koujirou Yamamoto; Hisakazu Ohtani
Journal:  Drug Metab Dispos       Date:  2011-01-06       Impact factor: 3.922

Review 4.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

5.  RS-Predictor models augmented with SMARTCyp reactivities: robust metabolic regioselectivity predictions for nine CYP isozymes.

Authors:  Jed Zaretzki; Patrik Rydberg; Charles Bergeron; Kristin P Bennett; Lars Olsen; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2012-05-29       Impact factor: 4.956

Review 6.  Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

Authors:  Naiem T Issa; Henri Wathieu; Abiola Ojo; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 7.  Modelling three-dimensional protein structures for applications in drug design.

Authors:  Tobias Schmidt; Andreas Bergner; Torsten Schwede
Journal:  Drug Discov Today       Date:  2013-11-08       Impact factor: 7.851

Review 8.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

9.  Molecular evolution of the CYP2D subfamily in primates: purifying selection on substrate recognition sites without the frequent or long-tract gene conversion.

Authors:  Yoshiki Yasukochi; Yoko Satta
Journal:  Genome Biol Evol       Date:  2015-03-25       Impact factor: 3.416

10.  Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations.

Authors:  Gabor Nagy; Chris Oostenbrink
Journal:  Eur Biophys J       Date:  2012-10-20       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.